05
Mar
2010
Posted in I - Series C, Q - 1Q10, R - WEST, X - Asthma, X - COPD, XX - CA
Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.